SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

doi:10.4166/kjg.2021.110

SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID

Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.

Original language	English
Pages (from-to)	117-128
Number of pages	12
Journal	The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume	78
Issue number	2
DOIs	https://doi.org/10.4166/kjg.2021.110
State	Published - 25 Aug 2021

Keywords

COVID-19
COVID-19 vaccines
Inflammatory bowel diseases
SARS-CoV-2

Access to Document

10.4166/kjg.2021.110

Cite this

@article{2706611588f9424fbfc729ad572158ce,

title = "SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID",

abstract = "Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.",

keywords = "COVID-19, COVID-19 vaccines, Inflammatory bowel diseases, SARS-CoV-2",

author = "{Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases} and Lee, {Yoo Jin} and Kim, {Seong Eun} and Park, {Yong Eun} and Chang, {Ji Young} and Song, {Hyun Joo} and Kim, {Duk Hwan} and Yang, {Young Joo} and Kim, {Byung Chang} and Lee, {Jae Gon} and Yang, {Hee Chan} and Miyoung Choi and Myung, {Seung Jae}",

year = "2021",

month = aug,

day = "25",

doi = "10.4166/kjg.2021.110",

language = "English",

volume = "78",

pages = "117--128",

journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",

issn = "1598-9992",

publisher = "Korean Society of Gastroenterology",

number = "2",

}

SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID. / Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases.
In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 78, No. 2, 25.08.2021, p. 117-128.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease

T2 - Expert Consensus Statements by KASID

AU - Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases

AU - Lee, Yoo Jin

AU - Kim, Seong Eun

AU - Park, Yong Eun

AU - Chang, Ji Young

AU - Song, Hyun Joo

AU - Kim, Duk Hwan

AU - Yang, Young Joo

AU - Kim, Byung Chang

AU - Lee, Jae Gon

AU - Yang, Hee Chan

AU - Choi, Miyoung

AU - Myung, Seung Jae

PY - 2021/8/25

Y1 - 2021/8/25

N2 - Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.

AB - Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, is threatening global health worldwide with unprecedented contagiousness and severity. The best strategy to overcome COVID-19 is a vaccine. Various vaccines are currently being developed, and mass vaccination is in progress. Despite the very encouraging clinical trial results of these vaccines, there is insufficient information on the safety and efficacy of vaccines for inflammatory bowel disease (IBD) patients facing various issues. After reviewing current evidence and international guidelines, the Korean Association for the Study of Intestinal Diseases (KASID) developed an expert consensus statement on COVID-19 vaccination issues for Korean IBD patients. This expert consensus statement emphasizes that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination be strongly recommended for IBD patients, and it is safe for IBD patients receiving immunomodulatory therapy.

KW - COVID-19

KW - COVID-19 vaccines

KW - Inflammatory bowel diseases

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85115179267&partnerID=8YFLogxK

U2 - 10.4166/kjg.2021.110

DO - 10.4166/kjg.2021.110

M3 - Review article

C2 - 34446634

AN - SCOPUS:85115179267

SN - 1598-9992

VL - 78

SP - 117

EP - 128

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

IS - 2

ER -

SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID

Abstract

Keywords

Access to Document

Fingerprint

Cite this